Ligand id: 8089

Name: bermekimab

Compound class Antibody
International Nonproprietary Names
INN number INN
10806 bermekimab
MABp1 | RA-18C3 | Xilonix® (proposed trade name)
Bermekimab (MABp1, Xilonix) is an investigational fully human monoclonal antibody targeting IL-1α, with potential antiinflammatory action. This antibody is the first genuinely human monoclonal antibody to be produced directly from an affinity matured, human immune response. As MABp1 has not been subject to in vitro sequence modification it is predicted to have improved tolerability compared to antibodies that are 'humanised'.
A patent search suggests that Xilonix is the subject of WO2009148575 [3].
Database Links
Specialist databases
IMGT/mAb-DB 544
Other databases
GtoPdb PubChem SID 249565769
Search PubMed clinical trials bermekimab
Search PubMed titles bermekimab
Search PubMed titles/abstracts bermekimab